Key Takeaways
PharmaTher Holdings Ltd. (OTCQB: PHRRF) is highlighting a strategic opportunity for its ketamine-based therapies after a US executive order signed April 18 aims to accelerate the development of psychedelic drugs for serious mental illness.
"We believe the regulatory environment is beginning to open in both psychedelics and peptides, and we have already positioned the Company with PatchPrint and PharmaPatch," Fabio Chianelli, Chief Executive Officer of PharmaTher, said in a statement.
The order, "Accelerating Medical Treatments for Serious Mental Illness," directs the Food and Drug Administration to speed up review for designated psychedelic drugs and allocates at least $50 million in funding for research. The news sent psychedelic-focused stocks soaring, with Compass Pathways (CMPS) climbing as much as 50 percent and Atai Life Sciences (ATAI) jumping over 30 percent.
While the order specifically named compounds like psilocybin and ibogaine, PharmaTher believes the broad policy support for psychedelic medicine creates a significant tailwind for its entire platform, which includes a microneedle patch for ketamine that has completed IND-enabling studies.
The presidential directive instructs the FDA to issue "national priority vouchers" to psychedelic drugs that have already received Breakthrough Therapy designation, a move that could shorten review timelines from months to weeks. The administration also directed the FDA and Drug Enforcement Administration to establish an access pathway for certain compounds under the Right to Try Act for military veterans.
The market's reaction was immediate. Shares of Compass Pathways, which is developing a psilocybin therapy for treatment-resistant depression, rose 50 percent on Monday. Other companies in the sector, including GH Research and Definium Therapeutics, also saw double-digit percentage gains. Analysts at RBC Capital Markets told investors the order was a "substantial step towards diminishing regulatory risk," while Jefferies noted that "the path to commercialization could be even faster now."
For PharmaTher, the executive order provides a tailwind for its strategy focused on alternative delivery methods for psychedelics. The company is developing its PharmaPatch, a microneedle patch technology, to deliver ketamine and other compounds. The company believes this method offers advantages over traditional oral or injectable delivery by improving convenience and dosing control.
The executive order signals a major reduction in regulatory risk for the entire psychedelic sector. Investors will now watch for the FDA's issuance of priority review vouchers and the advancement of PharmaTher's ketamine patch through the clinical trial process.
This article is for informational purposes only and does not constitute investment advice.
